Stefania Gessi

List of Publications by Year in Descending Order

154 papers	7,912 citations	51 h-index	84 g-index
163 ext. papers	8,935 ext. citations	6.6 avg, IF	5.61 L-index

#	Paper	IF	Citations
154	Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
153	Antioxidant and Antiinflammatory Effects of , and Plant Extracts in Macrophage and Microglial Cells. *Cells*, **2021**, 10,	7.9	3
152	An Open Question: Is the A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?. *Frontiers in Pharmacology*, **2021**, 12, 652455	5.6	8
151	Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2021**, 80, 1105-1117	4.3	7
150	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. *Cells*, **2021**, 10,	7.9	4
149	A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease. *Cells*, **2021**, 10,	7.9	3
148	The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through AAR Positive Allosteric Modulation. *Cells*, **2020**, 9,	7.9	6
147	Adenosinergic System Involvement in Ischemic Stroke Patients' Lymphocytes. *Cells*, **2020**, 9,	7.9	1
146	Synthesis, biological evaluation and docking studies of a novel class of sulfur-bridged diazabicyclo[3.3.1]nonanes. *Bioorganic Chemistry*, **2020**, 102, 104072	5.1	
145	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. *Cells*, **2020**, 9,	7.9	7
144	A Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?. *Frontiers in Pharmacology*, **2020**, 11, 625134	5.6	2
143	Signaling pathways involved in anti-inflammatory effects of Pulsed Electromagnetic Field in microglial cells. *Cytokine*, **2020**, 125, 154777	4	6
142	Targeting A3 and A2A adenosine receptors in the fight against cancer. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 669-678	6.4	16
141	Pulsed electromagnetic field and relief of hypoxia-induced neuronal cell death: The signaling pathway. *Journal of Cellular Physiology*, **2019**, 234, 15089	7	19
140	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands. *ChemMedChem*, **2018**, 13, 1102-1114	3.7	1
139	A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. *Medicinal Research Reviews*, **2018**, 38, 1031-1072	14.4	82
138	Adenosine Receptors and Current Opportunities to Treat Cancer **2018**, 543-555		5

137	Adenosine Receptors: Structure, Distribution, and Signal Transduction **2018**, 33-57		9
136	Pharmacology of Adenosine Receptors: The State of the Art. *Physiological Reviews*, **2018**, 98, 1591-1625	47.9	259
135	Adenosine Receptors: The Status of the Art **2018**, 1-11		1
134	Pathological overproduction: the bad side of adenosine. *British Journal of Pharmacology*, **2017**, 174, 1945-1960	5.6	64
133	Deregulation of Adenosine Receptors in Psoriatic Epidermis: An Option for Therapeutic Treatment. *Journal of Investigative Dermatology*, **2017**, 137, 11-13	4.3	7
132	A adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway. *Pharmacological Research*, **2017**, 117, 9-19	10.2	42
131	Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists. *Medicinal Research Reviews*, **2017**, 37, 936-983	14.4	47
130	Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields. *Mediators of Inflammation*, **2017**, 2017, 2740963	4.3	39
129	The Role of Adenosine Receptors in Psychostimulant Addiction. *Frontiers in Pharmacology*, **2017**, 8, 985	5.6	46
128	Biochemical and Pharmacological Role of A Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy. *Advances in Experimental Medicine and Biology*, **2017**, 1051, 193-232	3.6	31
127	Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells. *Journal of Cellular Physiology*, **2017**, 232, 1200-1208	7	32
126	Inhibition of A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. *Frontiers in Pharmacology*, **2017**, 8, 888	5.6	32
125	Role and Function of A and A Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	38
124	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB receptor antagonists/inverse agonists. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5291-5301	3.4	12
123	Positive allosteric modulation of A adenosine receptors as a novel and promising therapeutic strategy for anxiety. *Neuropharmacology*, **2016**, 111, 283-292	5.5	24
122	The activation of opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia. *FEBS Letters*, **2016**, 590, 2813-26	3.8	49
121	Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?. *Trends in Pharmacological Sciences*, **2016**, 37, 419-434	13.2	174
120	Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype. *Pharmacological Research*, **2015**, 99, 229-36	10.2	27

119	The A3 adenosine receptor: history and perspectives. *Pharmacological Reviews*, **2015**, 67, 74-102	22.5	162
118	van't Hoff Based Thermodynamics. *Methods and Principles in Medicinal Chemistry*, **2015**, 15-35	0.4	2
117	A and a adenosine receptors affect HIF-1 signaling in activated primary microglial cells. *Glia*, **2015**, 63, 1933-1952	9	33
116	Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. *Medicinal Chemistry*, **2015**, 11, 342-53	1.8	6
115	TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. *Neuropharmacology*, **2014**, 81, 6-14	5.5	46
114	Targeting adenosine receptors to prevent inflammatory skin diseases. *Experimental Dermatology*, **2014**, 23, 553-4	4	7
113	Morphine mediates a proinflammatory phenotype via opioid receptor-PKCe-Akt-ERK1/2 signaling pathway in activated microglial cells. *Biochemical Pharmacology*, **2013**, 86, 487-96	6	70
112	A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. *Pharmacological Research*, **2013**, 76, 157-70	10.2	39
111	Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. *Pain*, **2013**, 154, 864-73	8	49
110	Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated. *European Journal of Immunology*, **2013**, 43, 2206-16	6.1	37
109	A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. *PLoS ONE*, **2013**, 8, e54195	3.7	37
108	Pulsed electromagnetic fields increased the anti-inflammatory effect of A and A adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. *PLoS ONE*, **2013**, 8, e65561	3.7	84
107	Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. *British Journal of Pharmacology*, **2012**, 166, 2371-85	8.6	46
106	Downregulation of A(1) and A(2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 1660-70	6.9	9
105	Hydrogen sulfide modulates the release of nitric oxide and VEGF in human keratinocytes. *Pharmacological Research*, **2012**, 66, 428-36	10.2	31
104	Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2012**, 55, 5380-90	8.3	10
103	The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. *PLoS ONE*, **2012**, 7, e39317	3.7	31
102	Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. *British Journal of Pharmacology*, **2012**, 165, 1773-1788	8.6	39

101	Adenosine receptors and cancer. *Biochimica Et Biophysica Acta - Biomembranes*, **2011**, 1808, 1400-12	3.8	158
100	Adenosine receptor targeting in health and disease. *Expert Opinion on Investigational Drugs*, **2011**, 20, 1591-609	5.9	62
99	Adenosine receptors in health and disease. *Advances in Pharmacology*, **2011**, 61, 41-75	5.7	59
98	A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. *FASEB Journal*, **2010**, 24, 587-98	0.9	97
97	Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 90-7	9.4	65
96	Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. *Current Medicinal Chemistry*, **2010**, 17, 3488-502	4.3	37
95	Glucocorticoid pharmacology: past, present and future. *Current Pharmaceutical Design*, **2010**, 16, 3540-53	3.3	25
94	Thermodynamic Analysis in Drug-Receptor Binding: The A3 Adenosine Receptor **2010**, 29-48		
93	Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. *Biochemical Pharmacology*, **2010**, 79, 471-7	6	20
92	Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. *Biochemical Pharmacology*, **2010**, 79, 1483-95	6	57
91	A3 Adenosine Receptor Regulation of Cells of the Immune System and Modulation of Inflammation **2010**, 235-256		4
90	Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications **2010**, 301-317		2
89	A3 Adenosine Receptors, HIF-1 Modulation and Atherosclerosis **2010**, 281-288		
88	Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2009**, 1792, 531-40	6.9	22
87	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. *Neoplasia*, **2009**, 11, 1064-73	6.4	59
86	Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour. *Biochemical Pharmacology*, **2008**, 75, 562-9	6	17
85	Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors. *Biochemical Pharmacology*, **2008**, 75, 1198-208	6	9
84	Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. *Osteoarthritis and Cartilage*, **2008**, 16, 292-304	6.2	98

83	Pharmacological characterization of P2X1 and P2X3 purinergic receptors in bovine chondrocytes. *Osteoarthritis and Cartilage*, **2008**, 16, 1421-9	6.2	31
82	The A3 adenosine receptor: an enigmatic player in cell biology **2008**, 117, 123-40		177
81	The P2X7 receptor as a therapeutic target. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 647-61	6.4	73
80	Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. *Chemical Reviews*, **2008**, 108, 238-63	68.1	196
79	Therapeutic potential of adenosine receptor antagonists and agonists. *Expert Opinion on Therapeutic Patents*, **2007**, 17, 979-91	6.8	22
78	From tyrosine to glycine: synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 3706-15	8.3	11
77	Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. *Journal of Cellular Physiology*, **2007**, 211, 826-36	7	96
76	N(6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5RN-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2514-27	3.4	52
75	Adenosine and lymphocyte regulation. *Purinergic Signalling*, **2007**, 3, 109-16	3.8	62
74	Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. *Molecular Pharmacology*, **2007**, 72, 395-406	4.3	136
73	Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. *Molecular Pharmacology*, **2007**, 72, 162-72	4.3	70
72	Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. *Biochemical Pharmacology*, **2006**, 72, 19-31	6	106
71	Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 398-406	10.2	92
70	Synthesis of 3,6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 676-91	3.4	15
69	Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors. *Purinergic Signalling*, **2006**, 2, 583-8	3.8	6
68	Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A□adenosine receptor. *Purinergic Signalling*, **2006**, 2, 627-32	3.8	30
67	Synthesis and pharmacology of 6-substituted benztropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter. *Journal of Medicinal Chemistry*, **2005**, 48, 3337-43	8.3	8
66	A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. *Neoplasia*, **2005**, 7, 894-903	6.4	70

65	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. *Biochemical Pharmacology*, **2005**, 70, 1601-12	6	51
64	Synthesis and Biological Evaluation of Allosteric A1-Adenosine Receptor Modulators Structurally Related to (2-Amino-4,5,6,7-Tetrahydro-Benzo[B]Thiophen-3-YL)-(4-Chloro-Phenyl)-Methanone, a Potent Compound Useful to Reduce Neuropathic Pain. *Medicinal Chemistry Research*, **2005**, 14, 125-142	2.2	4
63	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines. *Current Medicinal Chemistry*, **2005**, 12, 1319-29	4.3	32
62	A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. *Journal of Biological Chemistry*, **2005**, 280, 19516-26	5.4	98
61	Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20. *Molecular Pharmacology*, **2005**, 67, 2137-47	4.3	58
60	Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. *Molecular Pharmacology*, **2004**, 65, 711-9	4.3	72
59	Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. *FASEB Journal*, **2004**, 18, 884-6	0.9	56
58	Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. *Clinical Cancer Research*, **2004**, 10, 5895-901	12.9	340
57	[3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3607-10	2.9	34
56	Synthesis, radiolabeling, and preliminary biological evaluation of [3H]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl)-piperazine, a potent antagonist radioligand for the P2X7 receptor. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5709-12	2.9	11
55	Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2004**, 47, 1434-47	8.3	298
54	Characterization of intrinsic sympathomimetic activity of carteolol in rat cardiovascular preparations. *Journal of Pharmacological Sciences*, **2004**, 95, 115-23	3.7	11
53	Receptor binding thermodynamics at the neuronal nicotinic receptor. *Current Topics in Medicinal Chemistry*, **2004**, 4, 361-8	3	20
52	New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2003**, 367, 109-18	3.4	12
51	Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. *Biochemical Pharmacology*, **2003**, 66, 739-48	6	227
50	Alteration of A(3) adenosine receptors in human neutrophils and low frequency electromagnetic fields. *Biochemical Pharmacology*, **2003**, 66, 1897-906	6	26
49	A glance at adenosine receptors: novel target for antitumor therapy **2003**, 100, 31-48		373
48	Recent developments in the field of A3 adenosine receptor antagonists. *Drug Development Research*, **2003**, 58, 315-329	5.1	27

47	Adenosine receptors and human melanoma. *Drug Development Research*, **2003**, 58, 377-385	5.1	10
46	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation. *Journal of Medicinal Chemistry*, **2003**, 46, 4287-96	8.3	50
45	Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 1229-41	8.3	63
44	Binding thermodynamics at the human A(3) adenosine receptor. *Biochemical Pharmacology*, **2002**, 63, 157-61	6	25
43	A convenient synthesis by microwave heating and pharmacological evaluation of novel benzoyltriazole and saccharine derivatives as 5-HT(1A) receptor ligands. *European Journal of Pharmaceutical Sciences*, **2002**, 16, 15-28	5.1	27
42	Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. *Journal of Investigative Dermatology*, **2002**, 119, 923-33	4.3	115
41	Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. *British Journal of Pharmacology*, **2002**, 136, 57-66	8.6	100
40	A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. *Molecular Pharmacology*, **2002**, 61, 415-24	4.3	317
39	Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2002**, 45, 770-80	8.3	90
38	Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 823-7	2.9	14
37	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A3 adenosine receptor. *Drug Development Research*, **2001**, 52, 406-415	5.1	10
36	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists. *Drug Development Research*, **2001**, 53, 225-235	5.1	19
35	Synthesis by microwave irradiation and binding properties of novel 5-HT1A receptor ligands. *European Journal of Medicinal Chemistry*, **2001**, 36, 873-886	6.8	25
34	Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. *British Journal of Pharmacology*, **2001**, 134, 116-26	8.6	88
33	Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. *British Journal of Pharmacology*, **2001**, 134, 1215-26	8.6	93
32	Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. *Journal of Medicinal Chemistry*, **2001**, 44, 2735-42	8.3	36
31	Platelet alpha2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol. *Journal of Hypertension*, **2000**, 18, 217-21	1.9	10
30	Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 209-11	2.9	18

29	A(2A) adenosine receptors in human peripheral blood cells. *British Journal of Pharmacology*, **2000**, 129, 2-11	8.6	124
28	Synthesis, modelling, and mu-opioid receptor affinity of N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicycl. *Il Farmaco*, **2000**, 55, 553-62		14
27	Synthesis and preliminary biological evaluation of novel N-substituted 1-amino-3-[1-methyl(phenyl)-1H-indazol-4-yloxy]-propan-2-ols interesting as potential antiarrhythmic, local anaesthetic and analgesic agents. *Arzneimittelforschung*, **2000**, 50, 963-72		12
26	Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. *Circulation*, **2000**, 102, 285-9	16.7	92
25	Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. *Journal of Medicinal Chemistry*, **2000**, 43, 2805-13	8.3	66
24	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. *Journal of Medicinal Chemistry*, **2000**, 43, 4768-80	8.3	82
23	Synthesis, molecular modeling, and opioid receptor affinity of 9, 10-diazatricyclo[4.2.1.1(2,5)]decanes and 2,7-diazatricyclo[4.4.0. 0(3,8)]decanes structurally related to 3,8-diazabicyclo[3.2. 1]octanes. *Journal of Medicinal Chemistry*, **2000**, 43, 2115-23	8.3	10
22	4-(4-Fluorobenzoyl)-1-[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: synthesis and affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors. *European Journal of Medicinal Chemistry*, **1999**, 34, 843-852	6.8	6
21	Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. *British Journal of Clinical Pharmacology*, **1999**, 47, 167-72	3.8	36
20	Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1999**, 359, 7-10	3.4	148
19	Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1999**, 360, 270-7	3.4	36
18	Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy. *Neuroscience*, **1999**, 92, 1043-9	3.9	29
17	Early changes in adenosine A1 receptors in cerebral cortex slices submitted to in vitro ischemia. *Neurochemistry International*, **1999**, 34, 517-22	4.4	4
16	Alpha2-adrenergic agonist modulation of [35S]GTPgammaS binding to guanine-nucleotide-binding-proteins in human platelet membranes. *Life Sciences*, **1999**, 64, 1403-13	6.8	10
15	Temperature dependence and GABA modulation of beta-carboline binding to rat cerebellum benzodiazepine receptors. *Life Sciences*, **1999**, 64, PL185-92	6.8	3
14	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 4473-8	8.3	75
13	[3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes. *British Journal of Pharmacology*, **1998**, 123, 1723-31	8.6	51
12	Receptor binding thermodynamics as a tool for linking drug efficacy and affinity. *Il Farmaco*, **1998**, 53, 249-54		30

11	Benzocondensed derivatives as rigid analogues of the mu-opioid agonist 3(8)-cinnamyl-8(3)-propionyl-3,8-diazabicyclo[3.2.1]octanes: synthesis, modeling, and affinity. *Il Farmaco*, **1998**, 53, 667-74		2
10	Adenosine A2A receptors of human circulating blood elements. *Drug Development Research*, **1998**, 45, 253-260	5.1	4
9	Simplified analogues of ritanserin and their affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors. *European Journal of Medicinal Chemistry*, **1998**, 33, 705-713	6.8	1
8	Binding thermodynamics at the human neuronal nicotine receptor. *Biochemical Pharmacology*, **1998** , 55, 1189-97	6	35
7	Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding. *British Journal of Pharmacology*, **1997**, 122, 386-92	8.6	36
6	Human vascular kinin receptors of the B2 type characterized by radioligand binding. *British Journal of Pharmacology*, **1997**, 122, 1450-4	8.6	15
5	Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. *British Journal of Pharmacology*, **1996**, 117, 1693-701	8.6	71
4	The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. *British Journal of Pharmacology*, **1996**, 118, 1278-84	8.6	49
3	Binding thermodynamics at A1 and A2A adenosine receptors. *Life Sciences*, **1996**, 59, 1373-88	6.8	70
2	Thermodynamics of 5-HT3 receptor binding discriminates agonistic from antagonistic behaviour. *European Journal of Pharmacology*, **1996**, 298, 329-34	5.3	26
1	Binding thermodynamics of 5-HT1A receptor ligands. *European Journal of Pharmacology*, **1996**, 312, 107-14	5.3	23